Status:

COMPLETED

Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia

Lead Sponsor:

Fudan University

Conditions:

Atypical Endometrial Hyperplasia

Eligibility:

FEMALE

18-45 years

Phase:

PHASE2

PHASE3

Brief Summary

To see if megestrol acetate plus rosuvastatin will be superior to reversing the endometrial lesion to a normal endometrium than megestrol acetate alone in patients with atypical endometrial hyperplasi...

Detailed Description

After diagnosed of AEH by hysteroscopy, patients will be enrolled. Age, height, weight, waist circumstances, blood pressure, basic history of infertility and blood pressure will be collected. Blood te...

Eligibility Criteria

Inclusion

  • Have a confirmed pathological diagnosis based upon hysteroscopy
  • Have a desire for remaining reproductive function or uterus
  • Good compliance with adjunctive treatment and follow-up
  • Abnormal blood lipid. At least meet one of the following five items:
  • Total cholesterol (TC) ≥ 5.2mmol/L (200mg/dL)
  • Low-density lipoprotein cholesterol (LDL-C) ≥ 3.4mmol/L (130mg/dL)
  • Fasting triglycerides (TG) ≥ 1.7mmol/L (150mg/dL)
  • High-density lipoprotein cholesterol (HDL-C) \< 1.03mmol/L (40mg/dL)
  • Apo-lipoprotein-A (Apo-A) \< 1.0g/L

Exclusion

  • Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
  • Pregnancy or potential pregnancy
  • Under treatment of high-dose progestin therapy more than 1 months in recent 6 months
  • Confirmed diagnosis of any cancer in reproductive system
  • Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
  • Hypersensitivity or contradiction for using MA or statins
  • Already diagnosed with hyperlipidemia and using lipid-lowering drugs
  • With other factors of reproductive dysfunction;
  • Strong request for uterine removal or other conservative treatment
  • Smoker (\>15 cigarettes a day)
  • Drinker (\>20 grams a day)

Key Trial Info

Start Date :

September 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 20 2022

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT04491682

Start Date

September 1 2020

End Date

June 20 2022

Last Update

January 29 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Obstetrics and Gynecology Hospital, Fudan University

Shanghai, China